Actively Recruiting

Age: 28Days +
All Genders
NCT06265363

Evaluation of the Frequency, Risk Factors, and Outcomes of ROP in Infants With a BW >1500 Grs or GA ≥33 Wks in Turkey.

Led by Baskent University Ankara Hospital · Updated on 2024-11-01

1000

Participants Needed

1

Research Sites

69 weeks

Total Duration

On this page

Sponsors

B

Baskent University Ankara Hospital

Lead Sponsor

H

Hacettepe University

Collaborating Sponsor

AI-Summary

What this Trial Is About

The study includes preterm infants who are being screened for ROP between August 1,2023 and August 1, 2024 in 94 neonatal intensive care units (NICUs) in Turkey. Infants with birth weight (BW) of \>1500 g or ≥ 33 weeks' gestation who are screened for retinopathy of prematurity are included. The incidence of any ROP, severe ROP and treatment modalities will be determined. The risk factors for ROP development will also be evaluated.

CONDITIONS

Official Title

Evaluation of the Frequency, Risk Factors, and Outcomes of ROP in Infants With a BW >1500 Grs or GA ≥33 Wks in Turkey.

Who Can Participate

Age: 28Days +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Infants with birth weight over 1500 grams or gestational age 33 weeks or less who are considered at risk for retinopathy of prematurity and have been screened for ROP.
Not Eligible

You will not qualify if you...

  • Neonates who died before their first retinopathy of prematurity examination.

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Baskent University

Ankara, Turkey (Türkiye)

Actively Recruiting

Loading map...

Research Team

S

Sezin Unal

CONTACT

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

0

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here